#genetics #cardiomyopathy #dilated-cardiomyopathy #atrial-fibrillation #rare-variants

TTN (Titin)

Details

TTN encodes titin, the largest human protein (~3.7 MDa), spanning the entire half-sarcomere from Z-disc to M-line as the third sarcomeric filament alongside actin and myosin. Titin acts simultaneously as a molecular spring governing passive myocardial stiffness, a scaffold for sarcomere assembly, and a signalling hub integrating mechanical, metabolic, and post-translational inputs. Rare loss-of-function truncating variants (TTNtv) are the single most common monogenic cause of dilated cardiomyopathy (DCM) and the most frequently identified disease-associated rare variants in early-onset atrial fibrillation (EOAF). Pathogenicity is critically location-dependent: variants in the constitutively expressed A-band carry OR ~50 for DCM, whereas low-exon-expression I-band variants approach population frequency. Disease penetrance is variable and substantially modified by common variant background (PRS) and environmental second hits (alcohol, pregnancy, cardiotoxic therapy).

Epidemiology

DCM — most common gene: TTNtv account for ~25% of familial DCM and ~18% of sporadic DCM. (sources/esc-cmp-2023, sources/HF-ESC-2021, rating: very high)
Early-onset AF (EOAF): In a 1,293-patient EOAF panel study (Yoneda), TTN harboured the most P/LP variants (38 participants, 3% of EOAF cohort); prevalence rises to 4.7% for EOAF onset <40 years, 6.5% for onset <30 years, and 16% in familial AF (Jurgens). (sources/eoaf-jama-2021, sources/genetic-eoaf-ehj-2024, rating: high)
UK Biobank population (n=403,990): TTN pLOF variants were the strongest and most prevalent rare genetic risk factor for AF; PSI90 isoform-restricted TTNtv OR 3.85 (95% CI 3.25–4.55; P=1.09×10⁻⁵⁵). (sources/Biobank-AF-JAMA-2024, rating: high)
Combined cardiomyopathy + arrhythmia panel (n=4,782): TTN was the 2nd most common gene with P/LP variants (11.7% of all P/LP carriers), behind only MYBPC3 (16.7%) and ahead of MYH7 (9.0%). (sources/genetic-yield-jama-card-2022, rating: high)
General population TTNtv prevalence: ~1% of the general population carry a TTNtv; the majority are asymptomatic, underlining the importance of location and second-hit context in penetrance. (sources/TTN-CVResearch-2022, rating: high)

Genetics

Inheritance and Penetrance

Autosomal dominant, variable penetrance. Many TTNtv carriers remain clinically unaffected throughout life, particularly those with low-PSI (low constitutive expression) I-band variants or those unexposed to environmental second hits. (sources/TTN-CVResearch-2022, rating: high)
PRS modifies TTNtv AF penetrance 3-fold: In ~44,000 UK Biobank participants, TTNtv carriers in the highest common-variant AF PRS tertile had 21.5% AF prevalence vs. 6.7% in the lowest tertile — confirming that rare TTN LOF and common variant background act as independent additive AF risk layers. (sources/genetic-eoaf-ehj-2024, rating: high)
Second-hit concept: TTNtv confer markedly elevated cardiomyopathy risk when combined with environmental stressors — alcoholic CMP (TTNtv prevalence 13.5% vs. 2.9% controls), cancer therapy-induced CMP (7.5%), peripartum CMP (10%). A TTNtv carrier without environmental trigger exposure may never develop clinical disease. (sources/esc-cmp-2023, rating: high)

Variant Classification

Location determines pathogenicity:
- A-band TTNtv: DCM prevalence 10.74% vs. control 0.24%; OR 49.8 — highly pathogenic
- Constitutive I-band (high PSI): intermediate risk
- Central I-band (low PSI exons): DCM prevalence ~0.24% vs. 0.17% control; OR 1.5 — near population background
- Restricting to constitutively spliced-in cardiac exons (PSI ≥90%) substantially increases specificity of variant reporting. (sources/TTN-CVResearch-2022, sources/Biobank-AF-JAMA-2024, rating: high)
TTNtv vs. missense: Loss-of-function is the established disease mechanism. TTN missense variants are routinely excluded from clinical reporting due to high prevalence and uncertain significance — 494 missense variants were excluded in one major EOAF cohort. No validated functional assay distinguishes benign from pathogenic TTN missense variants in routine clinical practice. (sources/eoaf-jama-2021, rating: high)
VUS burden: TTN generates more loss-of-function VUSs than any other gene on cardiomyopathy/arrhythmia panels (98 LOF VUSs in one EOAF cohort) due to transcript length. Clinical management of a TTN LOF VUS in an AF patient is not guideline-specified. (sources/eoaf-jama-2021, rating: high)

Pathophysiology

Sarcomere Architecture and Isoforms

Titin spans the half-sarcomere from Z-disc to M-band in three functional zones: A-band (inextensible; thick-filament assembly template); I-band (elastic spring); Z-disc/M-band anchors. (sources/TTN-CVResearch-2022, rating: high)
The elastic I-band spring contains three extensible elements: PEVK repeats, Ig domains, and the N2B-unique sequence (N2Bus). These elements determine passive stiffness and compliance. (sources/TTN-CVResearch-2022, rating: high)
Human TTN has 364 exons. Four principal cardiac isoforms: N2B (3 MDa; short/stiff), N2BA (3.2–3.8 MDa; long/compliant), Novex-3 (~650 kDa; structural), Cronos (2.3 MDa; internal promoter; predominantly fetal, ~10% adult pool). Healthy adult LV N2BA:N2B ratio ~30:70. Isoform switching underlies HF-related stiffness changes. See concepts/Titin-Isoform-Switch. (sources/TTN-CVResearch-2022, rating: high)
Titin stiffness regulates length-dependent activation (Frank-Starling mechanism). Stiffer N2B-enriched titin → greater LDA → augmented cardiac output. N2BA-enriched compliant titin → blunted LDA → impaired output, as in HFrEF. (sources/TTN-CVResearch-2022, rating: high)

Post-Translational Modifications

Titin spring stiffness is fine-tuned beat-to-beat through three PTM types — see concepts/Titin-PTMs for full mechanistic detail.

Phosphorylation: N2Bus phosphorylation (PKA/PKG/PKD/ERK2/CaMKIIδ) → decreased stiffness; PEVK phosphorylation (PKCα/CaMKIIδ/PKD) → increased stiffness. In HF: N2Bus hypo-phosphorylation + PEVK hyper-phosphorylation → net increased passive stiffness. (sources/TTN-CVResearch-2022, rating: high)
Acetylation: Increased titin acetylation in HFpEF (reduced SIRT1 activity) → increased stiffness; NAD⁺/NAM restores SIRT1 → deacetylation → reduced stiffness in animal models. (sources/TTN-CVResearch-2022, rating: high)
Oxidation: Cryptic cysteines in unfolded Ig domains undergo S-glutathionylation (→ decreased stiffness) or disulphide bonding (→ increased stiffness). In HFpEF and ischaemia, oxidation becomes pathologically extensive. (sources/TTN-CVResearch-2022, rating: high)

TTNtv Cardiomyopathy — Molecular Pathomechanisms

Triple pathomechanism (Fomin et al., Sci Transl Med 2021): (sources/TTN-CVResearch-2022, rating: high)
1. Titin haploinsufficiency: Reduced wild-type titin → fewer sarcomeres per unit area → chronic contractile deficiency
2. Truncated protein toxicity (poison-peptide): Truncated titin stably expressed in adult hearts (up to 50% of titin pool); not incorporated into sarcomeres; sequestered as cytoplasmic aggregates. Higher truncated titin content correlates with younger age at transplantation
3. Protein quality control (PQC) failure: UPS overwhelmed and downregulated (reduced MuRF1); aggregate formation activates autophagy as partial compensation. NMD of TTNtv mRNA is NOT a prominent feature
CRISPR/Cas9 correction of TTNtv in hiPSC-CMs fully restores wild-type titin, eliminates truncated titin, and recovers contractility — strongest preclinical proof-of-concept for gene correction. (sources/TTN-CVResearch-2022, rating: high)
Metabolic reprogramming: TTNtv rat models show decreased titin protein, shift from fatty acid oxidation to glycolysis, and mTORC1 pathway activation — mirroring metabolic signatures of human DCM and explaining vulnerability to metabolic stressors (pregnancy, alcohol). (sources/HF-Precision-Medicine-AHA-2019, rating: high)
Less cardiac hypertrophy than LMNA, MYH7, or other genetic DCM forms when corrected for degree of cardiac dysfunction — reflecting the metabolic-sarcomere mechanism rather than a hypertrophic remodelling response. (sources/DCM-Lancet-2023, rating: very high)
Atrial myopathy hypothesis for EOAF: TTNtv may drive atrial structural dysfunction as the primary mechanism in isolated EOAF, prior to or independent of ventricular involvement — consistent with AF as the initial cardiomyopathy manifestation. (sources/eoaf-jama-2021, sources/genetic-eoaf-ehj-2024, rating: high)

Clinical Phenotypes

Dilated Cardiomyopathy / NDLVC

TTNtv is the most common genetic cause of DCM (15–25% of cohorts) and also the most common predisposition in restrictive, non-compaction, peripartum, alcoholic, and anthracycline-induced CMP. (sources/TTN-CVResearch-2022, rating: high)
CMR pattern: Heterogeneous LGE without the characteristic ring-like pattern of DSP/FLNC/PLN; often subepicardial or diffuse. May be normal early in disease or in EOAF-only phenotypes. (sources/esc-cmp-2023, rating: high)
Highest reverse remodeling rate among DCM genotypes: Up to 70% of TTN-related DCM patients achieve LVEF improvement on GDMT — higher than LMNA, RBM20, or MYH7-associated DCM. (sources/HF-ESC-2021, rating: very high)

Early-Onset Atrial Fibrillation

AF without LV dysfunction: In a prospective cohort of 122 EOAF patients (<40 years, no structural disease), TTN was the most common cardiomyopathy gene identified; CMR findings were normal at diagnosis. (sources/eoaf-riskfactor-ehj-2026, rating: medium)
Familial AF cohort — isolated atrial phenotype: TTNtv carriers with familial AF (median onset 26 years) had normal LA and LV dimensions at AF diagnosis and at multi-year follow-up — the strongest human evidence that TTNtv can cause clinically isolated AF in the complete absence of ventricular cardiomyopathy. (sources/genetic-af-dxmx-jce-2022, rating: medium)
AF precedes ventricular cardiomyopathy in ~50%: Among UK Biobank TTNtv carriers who eventually developed both AF and ventricular cardiomyopathy, AF was the first diagnosis in ~50% — directly challenging the assumption that AF is a downstream sequela of established DCM. (sources/genetic-eoaf-ehj-2024, rating: high)

Second-Hit Phenotypes

Alcoholic CMP: TTNtv prevalence 13.5% vs. 2.9% in controls. (sources/esc-cmp-2023, rating: high)
Cancer therapy–induced CMP: TTNtv in 7.5% of cases. (sources/esc-cmp-2023, rating: high)
Peripartum CMP: TTNtv in 10% of patients. (sources/esc-cmp-2023, rating: high)

Diagnosis

When to Test

DCM or unexplained LV dysfunction: TTN is included in the ESC 2021 minimum genetic panel for DCM/HNDC (alongside LMNA, MYH7, MYBPC3, TNNT2, RBM20, PLN, SCN5A, BAG3). (sources/HF-ESC-2021, rating: very high)
EOAF (especially onset <40 years or familial AF): TTN P/LP variants are the single most common rare variant finding on EOAF panels; testing is appropriate, particularly when AF is unexplained and CMR is normal. (sources/genetic-eoaf-ehj-2024, sources/Biobank-AF-JAMA-2024, rating: high)
Second-hit CMP: TTNtv testing is warranted in alcoholic, peripartum, and anthracycline-induced CMP given the high prevalence and counseling implications. (sources/esc-cmp-2023, rating: high)

Interpreting the Result

Accept only LOF variants (frameshift, nonsense, canonical splice) in constitutively expressed cardiac exons (PSI ≥90%): This is the validated reporting threshold. A-band TTNtv: OR ~50 for DCM (clearly pathogenic). Low-PSI I-band TTNtv: OR ~1.5 (near population risk — treat as VUS or benign). (sources/TTN-CVResearch-2022, sources/Biobank-AF-JAMA-2024, rating: high)
Exclude TTN missense from clinical reporting: No functional assay distinguishes benign from pathogenic TTN missense variants. (sources/eoaf-jama-2021, rating: high)
TTN LOF VUS in EOAF: The most common VUS scenario on arrhythmia/CMP panels; no guideline-specified management beyond standard AF care. Longitudinal phenotyping of the proband and first-degree relatives is the only practical approach. (sources/eoaf-jama-2021, rating: high)

Imaging at Diagnosis

CMR at time of TTNtv discovery: Even in EOAF carriers with normal LV function, CMR provides a fibrosis baseline. LGE may be absent early; subepicardial or diffuse LGE when present does not follow the ring pattern of DSP/PLN. (sources/esc-cmp-2023, rating: high)
Echo or CMR surveillance in EOAF-only carriers: AF may precede ventricular cardiomyopathy by years; LVEF and LV volumes should be serially monitored. Surveillance interval is not guideline-defined — expert consensus favours CMR every 2–3 years in asymptomatic EOAF carriers with TTNtv. (sources/genetic-eoaf-ehj-2024, rating: high)

Management

GDMT in TTN-DCM

Standard quadruple GDMT (ARNI/ACEi + beta-blocker + MRA + SGLT2i) applies. TTN-associated DCM has the highest LV reverse remodeling rate among DCM genotypes — up to 70% achieve LVEF improvement. (sources/HF-ESC-2021, rating: very high)
Do not withdraw GDMT after LVEF recovery: TRED-HF pilot data showed 44% relapse within 6 months after drug withdrawal in non-ischaemic DCM that achieved partial or complete LVEF recovery. TTN patients who transiently normalise LVEF remain at high relapse risk. (sources/HF-ESC-2021, rating: very high)

Device Therapy

TTN is classified among 10 genes conferring heightened arrhythmia risk in cardiomyopathy (alongside LMNA, RBM20, RYR2, SCN5A, FLNC, DSP, PLN, DES, ABCC9), warranting intensive monitoring for AF, VT, and heart block. (sources/genetic-yield-jama-card-2022, rating: high)
ICD threshold follows standard HFrEF criteria (LVEF ≤35%, ≥3 months GDMT): TTN does not carry an ESC variant-specific early ICD recommendation (unlike LMNA, which warrants ICD consideration at LVEF <45% with additional risk factors). If LVEF fails to recover after adequate GDMT, standard ICD criteria apply. (sources/HF-ESC-2021, rating: very high)
AF management: Standard rhythm/rate control and anticoagulation per AF guidelines. No TTN-specific AF treatment modification is recommended. (sources/eoaf-jama-2021, rating: high)

Second-Hit Counseling

Alcohol: Counsel TTNtv carriers to minimise alcohol intake; even moderate alcohol exposure confers substantially elevated CMP risk (TTNtv prevalence 13.5% in alcoholic CMP). (sources/esc-cmp-2023, rating: high)
Cardiotoxic chemotherapy: Alert oncologists and cardio-oncology teams before anthracycline-based or other cardiotoxic therapy; pre-treatment CMR baseline and intensified monitoring warranted. (sources/esc-cmp-2023, rating: high)
Pregnancy and peripartum CMP: Preconception counseling re: peripartum CMP risk (~10% in TTNtv carriers); cardiology co-management throughout pregnancy is recommended. (sources/esc-cmp-2023, rating: high)

Cascade Genetic Testing

First-degree relatives of confirmed TTNtv carriers should be offered genetic testing and, if cascade positive, phenotypic evaluation. (sources/HF-ESC-2021, rating: very high)
Penetrance is variable: cascade-positive relatives with a normal phenotype still warrant periodic cardiomyopathy surveillance, especially if exposed to second-hit triggers.

Contradictions / Open Questions

Pre-clinical titin-targeting therapies have failed in clinical trials: Multiple strategies reducing titin stiffness in animal models (cGMP-PKG axis: sildenafil, BNP, sGC stimulators; RBM20 inhibition) failed in large clinical trials in human HFpEF (RELAX, VITALITY, SOCRATES). Whether this reflects animal-to-human biological differences, patient heterogeneity, dosing, or pathway compartmentalization is unresolved — no approved titin-targeted therapy currently exists. (sources/TTN-CVResearch-2022, rating: high)
Does TTNtv always progress to ventricular cardiomyopathy, or is atrial-limited disease possible? The JCE 2022 familial AF cohort showed normal LA/LV dimensions at diagnosis and follow-up, suggesting some TTNtv carriers may have purely atrial phenotypes. By contrast, UK Biobank EHJ 2024 shows AF precedes cardiomyopathy in ~50% of TTNtv carriers who develop both. Penetrance may vary by PRS background, environmental triggers, or variant position — the expected natural history and optimal surveillance interval for TTNtv carriers with isolated EOAF is not established. (sources/genetic-af-dxmx-jce-2022, sources/genetic-eoaf-ehj-2024, rating: high)
Reverse remodeling vs. arrhythmia risk paradox: ESC 2021 reports TTN-associated DCM has both the highest LV reverse remodeling rate (up to 70%) and heightened atrial/ventricular arrhythmia risk. Whether LVEF normalisers have lower arrhythmia burden is uncharacterised — this matters for ICD decisions in recovered TTN-DCM patients. (sources/HF-ESC-2021, rating: very high)
TTN missense variants — a diagnostic gap: Routine exclusion of TTN missense variants from clinical reporting may miss rare pathogenic missense variants. No validated functional assay is available. The diagnostic gap is largest in index cases with intermediate-probability phenotypes (mild DCM, EOAF) where the difference between VUS and likely pathogenic changes clinical management. (sources/eoaf-jama-2021, rating: high)
Second-hit penetrance counseling not standardised: A TTNtv carrier who avoids alcohol, pregnancy-related stress, and cardiotoxic therapy may never develop clinical disease. Communicating conditional vs. absolute lifetime risk for each second-hit trigger requires individualized counseling that current guidelines do not provide a framework for. (sources/esc-cmp-2023, rating: high)

Connections

Related to entities/Atrial-Fibrillation
Related to entities/DCM
Related to entities/NDLVC
Related to entities/Heart-Failure
Related to concepts/Titin-Isoform-Switch
Related to concepts/Titin-PTMs
Related to concepts/Early-Onset-Atrial-Fibrillation
Related to concepts/Genetic-Testing-in-AF
Related to concepts/Genetic-Testing-in-Cardiomyopathy
Related to concepts/Arrhythmogenic-Cardiomyopathy
Related to concepts/VA-Risk-Stratification-DCM
Related to concepts/Cascade-Family-Screening